At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 282 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue
In Brief
A Phase 4 clinical trial evaluating Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, and 1 other intervention for Ocular Hypertension and Open Angle Glaucoma. Completed, enrolled 282 participants.
Detailed Summary
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Open Angle Glaucoma
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartOct 2013
Primary CompletionMay 2014
TodayJul 2026
First PostedSep 9, 2013
Enrollment StartOct 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.8 years ago
Interventions
Brinzolamide 1%/brimonidine 0.2% ophthalmic suspensiondrug
Vehicledrug
Inactive ingredients used as a placebo comparator
Prostaglandin analoguedrug